Kymera Therapeutics (KYMR) AI Stock Analysis

• Market Cap: $3.02B
• Dividend Yield: N/A
• Average Volume (3M): 631.62K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.56
• Revenue Growth: -49.51%
• EPS Growth: -44.09%
• Country: US
• Employees: 208
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): -0.95
• Shares Outstanding: 71,497,600
• 10 Day Avg. Volume: 611,124
• 30 Day Avg. Volume: 631,616
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 65.56
• Enterprise Value/Gross Profit: 68.76
• Enterprise Value/Ebitda: -10.58
• 1Y Price Target: $60.86
• Price Target Upside: 44.22% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16

• Rating: 57 Neutral
• Price Target: $45.00 ▲(6.64% Upside)

Kymera Therapeutics' overall stock score reflects a challenging financial performance with persistent losses and valuation concerns. However, the company's strong strategic partnerships and promising clinical advancements provide a positive outlook. Technical indicators suggest neutral momentum, while the earnings call and corporate events highlight significant growth potential.

Positive Factors

Competitive Advantage

Kymera Therapeutics remains significantly ahead of competitor STAT6 programs and owns full rights to the asset, strengthening its competitive position.

Partnership Opportunities

Kymera's ability to deliver highly specific differentiated degraders provides opportunities for non-dilutive capital in the form of partnerships with companies like Sanofi and Gilead.

Pipeline Success

Kymera is the first to reach the milestone with a STAT6 degrader, leading the race in targeting the Th2 inflammatory pathway.

Negative Factors

Clinical Efficacy Concerns

The robust Th2 biomarker suppression in BroADen may not necessarily translate into clinically meaningful EASI 75 and pruritus NRS improvements on Day 28.

Investor Confusion

The rationale for the second dose in the Ph 1b is driving some investor confusion.

Stock Volatility

The addition of a second dose in the Phase 1b study drove early weakness in shares, though it's unclear if the second dose is higher or lower.

Kymera Therapeutics Business Overview & Revenue Model

Company Description

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

How the Company Makes Money

Kymera Therapeutics makes money primarily through the development and potential commercialization of its drug candidates, leveraging its proprietary targeted protein degradation platform. Key revenue streams include research and development collaborations, milestone payments, and potential royalties from partnerships with larger pharmaceutical companies. These partnerships, such as those with Sanofi and Vertex Pharmaceuticals, provide funding and resources needed to advance Kymera's drug candidates through clinical trials. Additionally, as drug candidates progress and potentially receive regulatory approval, the company stands to earn revenue from product sales and licensing agreements.

Kymera Therapeutics Financial Statement Overview

Summary

Kymera Therapeutics faces financial challenges typical of biotechnology firms, with negative earnings and cash flow due to heavy R&D investments. While the balance sheet shows a strong equity position, ongoing losses and negative cash flows are concerning.

Income Statement

Kymera Therapeutics shows a declining revenue growth with a drop from the previous periods, and consistent negative net profit margins indicating an ongoing unprofitable state. The gross profit margin is solid as all revenue translates directly to gross profit due to likely no cost of goods sold, but the EBIT and EBITDA margins are significantly negative, reflecting high operational expenses that overshadow revenues.

Balance Sheet

The company maintains a robust equity position with a strong equity ratio, but the debt-to-equity ratio suggests manageable leverage. However, the return on equity remains negative due to persistent losses, which raises concerns about profitability. The balance sheet shows a solid cash position, but the high liabilities relative to equity warrant caution.

Cash Flow

Kymera Therapeutics faces negative free cash flow, which has deteriorated further, indicating pressure on cash generation. The operating cash flow is significantly negative, raising concerns about the company's ability to fund operations without external financing. The free cash flow to net income ratio is unreliable due to negative values, highlighting cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	44.71M	47.07M	78.59M	46.83M	72.83M	34.03M
Gross Profit	42.63M	47.07M	78.59M	43.85M	70.44M	-28.07M
EBITDA	-277.16M	-216.24M	-143.20M	-151.66M	-97.64M	-43.72M
Net Income	-275.43M	-223.86M	-146.96M	-151.83M	-98.00M	-43.95M
Balance Sheet
Total Assets	1.13B	978.03M	575.76M	603.13M	605.90M	487.18M
Cash, Cash Equivalents and Short-Term Investments	665.45M	488.74M	374.88M	559.49M	567.61M	458.73M
Total Debt	85.71M	87.76M	84.67M	17.34M	17.96M	17.99M
Total Liabilities	159.59M	142.42M	180.79M	112.98M	146.27M	203.29M
Stockholders Equity	971.48M	835.62M	394.97M	490.15M	459.64M	283.89M
Cash Flow
Free Cash Flow	-252.92M	-207.34M	-137.31M	-155.92M	-130.54M	79.03M
Operating Cash Flow	-251.01M	-194.50M	-102.83M	-153.09M	-128.95M	88.13M
Investing Cash Flow	19.52M	-404.08M	139.89M	20.52M	-99.83M	-422.59M
Financing Cash Flow	499.67M	608.85M	4.19M	153.00M	250.28M	289.26M

Kymera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 42.20
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KYMR, the sentiment is Positive. The current price of 42.2 is above the 20-day moving average (MA) of 41.81, below the 50-day MA of 43.51, and above the 200-day MA of 38.53, indicating a neutral trend. The MACD of -0.26 indicates Negative momentum. The RSI at 49.03 is Neutral, neither overbought nor oversold. The STOCH value of 47.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for KYMR.

Kymera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HRMY	78 Outperform	$2.13B	12.10	27.58%	―	17.74%	59.96%
AGIO	60 Neutral	$2.28B	3.68	64.05%	―	30.57%	―
KYMR	57 Neutral	$3.02B	―	-33.26%	―	-49.51%	-44.09%
BCRX	56 Neutral	$1.74B	―	18.68%	―	45.85%	76.36%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
BEAM	50 Neutral	$1.65B	―	-41.94%	―	-82.90%	-155.64%
IRON	43 Neutral	$2.09B	―	-26.36%	―	―	-22.19%

Kymera Therapeutics Corporate Events

Kymera Therapeutics Announces New Chief Legal Officer

On September 3, 2025, Kymera Therapeutics announced the retirement of Ellen Chiniara as Chief Legal Officer, with Brian R. Adams succeeding her. This leadership change is part of Kymera’s strategic efforts to advance its novel programs in the field of immunology, aiming to redefine treatment possibilities with groundbreaking oral medicines.

Kymera Therapeutics Announces Public Offering to Raise Funds

On June 26, 2025, Kymera Therapeutics announced an underwritten public offering of its common stock and pre-funded warrants, expected to raise approximately $237.3 million, with the potential to increase to $272.7 million if underwriters exercise their options fully. The proceeds will be used to advance Kymera’s clinical and preclinical degrader programs and for general corporate purposes. The offering is anticipated to close on June 30, 2025, subject to customary conditions, and is part of Kymera’s strategy to fund operations into mid-2028.

Kymera Therapeutics Holds Annual Shareholder Meeting

On June 25, 2025, Kymera Therapeutics held its Annual Meeting of Shareholders, where three key proposals were voted on. Shareholders elected Jeffrey Albers and Felix J. Baker as Class II directors for a three-year term, approved the compensation of named executive officers on a non-binding basis, and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Kymera Therapeutics Partners with Gilead for Oncology Treatment

On June 25, 2025, Kymera Therapeutics announced an exclusive option and license agreement with Gilead Sciences to develop novel oral molecular glue CDK2 degraders for oncology treatment, including breast cancer. The agreement could bring Kymera up to $750 million in payments and royalties, with Kymera leading research activities. This collaboration aims to advance cancer treatment by selectively targeting and degrading disease-driving proteins, potentially improving care for patients with high unmet medical needs.

Kymera Therapeutics Advances KT-485 in Sanofi Collaboration

On June 25, 2025, Kymera Therapeutics announced an update on its collaboration with Sanofi, highlighting the advancement of KT-485, an oral IRAK4 degrader, into clinical studies for immuno-inflammatory diseases. This decision, which includes a $20 million milestone achievement for Kymera, marks a strategic shift from KT-474 to KT-485, reflecting its superior preclinical profile and potential to transform immunology treatments. The collaboration could yield up to $975 million in clinical, regulatory, and commercial milestones, positioning Kymera strongly in the biopharmaceutical industry.